RECRUITING

All-extremity Exercise During Breast Cancer Chemotherapy

Conditions

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Currently, there are 3.5 million breast cancer survivors in the United States and this number is expected to increase dramatically. The proposed research will examine whether a novel exercise intervention for breast cancer patients who are undergoing chemotherapy protects against cardiovascular dysfunction. Findings may have implications for cardiovascular disease prevention in this population.

Official Title

All-extremity Exercise as a Novel Strategy for Optimizing Cardiovascular Function During Chemotherapy for Breast Cancer

Quick Facts

Study Start:2024-04-05
Study Completion:2026-05-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04914663

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 85 Years
Sexes Eligible for Study:FEMALE
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Active diagnosis of primary invasive non-metastatic breast cancer, stages I-III
  2. * Female
  3. * 18 to 85 years of age
  4. * Scheduled to initiate neoadjuvant or adjuvant chemotherapy (anthracycline, alkylating agent and/or taxane)
  5. * Absence of contraindications to exercise
  6. * Study clinician approval
  7. * Able to give consent
  8. * Informed consent obtained from the subject and documentation of subject agreement to comply with study-related process
  1. * Do not meet inclusion criteria
  2. * Receiving targeted therapies (CDK4/6 or PARP inhibitors)
  3. * Receiving radiation therapy concurrent with chemotherapy
  4. * Lymphedema stage ≥ 2 prior to study enrollment
  5. * Any relevant cardiovascular diseases (stroke, heart failure, myocardial ischemia during maximal graded exercise test, myocardial infarction, angina pectoris, coronary artery bypass surgery or angioplasty or coronary stent)
  6. * Current participation in other experimental interventions that may confound interpretation of study findings (e.g., dietary intervention for weight loss)

Contacts and Locations

Study Contact

Demetra Christou, PhD
CONTACT
3522941746
ddchristou@ufl.edu
Eileen Handberg
CONTACT
352-273-9082
handbem@medicine.ufl.edu

Principal Investigator

Demetra Christou, PhD
PRINCIPAL_INVESTIGATOR
University of Florida

Study Locations (Sites)

Integrative Cardiovasculal Physiology Laboratory, University of Florida
Gainesville, Florida, 32611
United States

Collaborators and Investigators

Sponsor: University of Florida

  • Demetra Christou, PhD, PRINCIPAL_INVESTIGATOR, University of Florida

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-04-05
Study Completion Date2026-05-31

Study Record Updates

Study Start Date2024-04-05
Study Completion Date2026-05-31

Terms related to this study

Additional Relevant MeSH Terms

  • Breast Cancer